Please login to the form below

Not currently logged in
Email:
Password:

Parsabiv

This page shows the latest Parsabiv news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication. Draft guidance recommends Amgen treatment for secondary hyperparathyroidism. ... Parsabiv was approved by the EMA last November and according to the company has advantages over its older drug.

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... to be used in clinical practice, the monthly costs of Parsabiv and Sensipar should be comparable.".

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    Amgen wins European approval for Parsabiv. Follows FDA knock-back in August for the chronic kidney disease treatment. ... In contrast, Parsabiv is administered as an infusion during dialysis, side-stepping the compliance issue.

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    FDA knocks back Amgen's chronic kidney disease treatment. Parsabiv was hoped to equal or exceed solid earner Sensipar. ... In contrast, Parsabiv is administered as an infusion during dialysis, side-stepping the compliance issue.

More from news
Approximately 4 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics